Palbociclib (PD-0332991) HCl

Licensed by Pfizer 製品コードS1116

Palbociclib (PD-0332991) HCl化学構造

分子量(MW):483.99

Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

サイズ 価格(税別)  
JPY 18260.00
JPY 28220.00
JPY 94620.00

カスタマーフィードバック(11)

  • FACS profiles for cell cycle synchronization of HCT116 cells pulsed with EdU. Asynchronous (AS) HCT116 cells were treated with CDK4/6i (Palbociclib, 2 μM) for 20 hours to arrest in G0/G1 (middle panel), followed by a wash in fresh media for 8 hours to release into S phase (right panel).

    Cell, 2018, 174(5):1127-1142. Palbociclib (PD-0332991) HCl purchased from Selleck.

    SK-HEP-1 cells were plated in the presence or absence of the CDK inhibitor (Roscovitine 10 mM; Palbociclib 500 nM). 18 hours after plating, cells were rinsed once with serum-free medium and incubated with delipidated medium containing the CDK inhibitor for 6 hours.

    Cell, 2018, doi:10.1016/j.cell.2018.11.011. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • PD-0332991 causes inhibition of proliferation of EAC cells in a dose-dependent manner. Western blots showing the phosphorylation status of pRB at Ser780 and Ser795 after incubation with 125 nmol/L PD-0332991 for 24 and 72 hours. Reduction in cyclin A expression and the expression of RB2 (p130) tumor suppressor 72 hours after PD-0332991 treatment are shown (bottom). Total pRB (RB1) and actin are loading controls and T293 cell lysate (293) is a positive control for total pRB and phospho-pRB (Ph-RB). E, anchorage-independent growth of the 3 cell lines in the presence or absence (Cnt) of 125 nmol/L PD-0332991 for 3 weeks.

    Clin Cancer Res 2011 17(13), 4513-22. Palbociclib (PD-0332991) HCl purchased from Selleck.

    b, c MelJuso cells were treated for 12–48 h with 1 µM Selumetinib or 5 µM Palbociclib and the cells were fixed, stained with propidium iodide and cell cycle distribution was determined by flow cytometry (b) and whole cell extracts were fractionated by SDS-PAGE, transferred onto PVDF membrane and immuno-blotted with the indicated antibodies (c). Data is from a single experiment representative of three separate experiments with similar results. The data in (b) are mean ± S.D. from a single experiment with three replicate dishes of cell per data point; similar results were obtained in two additional experiments

    Cell Mol Life Sci, 2016, 73(4):883-900. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • (A) Percentage of DN3a cells in S-phase (as gated on DAPI profile) from control (Zfp36l1/2fl/fl) and Zfp36l1/2fl/fl; CD2Cre (DCKO) mice, after 1 d of treatment with vector or palbociclib (drug).

    J Immunol, 2016, 197(7):2673-85. Palbociclib (PD-0332991) HCl purchased from Selleck.

     

    Patient tumor cell sensitivity to combinatorial treatment with histone deacetylase (HDAC)/cyclin-dependent kinase (CDK) inhibitors in 3-D culture. The effect of each drug or drug combination was assessed by fluorescent dye to identify live (green) and dead cells (red). Cells from breast reduction patients were used as non-cancer control in the assay.

    Pharmacogenomics J 2013 13(1), 94-104. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • The expression of respective proteins in CDK4/6-Rb-apoptosis pathway in cells was examined by Western blot after 3 days of palbociclib treatment.

    Biochim Biophys Acta, 2018, 1864(5 Pt A):1573-1582. Palbociclib (PD-0332991) HCl purchased from Selleck.

     

    Cdk4 is upregulated in ARMS and mMSCs transfected with PAX7-FKHR fusion gene (MP7F), and can be specifi cally inhibited. D: IF results showing overexpression of cdk4 in MP7F cells compared to parental mMSCs and reduced expression of cdk4 after treatment of MP7F cells with the cdk4 inhibitor, PD-0332991. E: IF results showing MyoD1 expression in parental mMSCs cells, and MP7F cells untreated and after treatment with the cdk4 inhibitor, PD-0332991.

    Clin Transl Oncol 2012 14(3), 197-206 . Palbociclib (PD-0332991) HCl purchased from Selleck.

  • WM3734 melanoma cells were treated by PD-0332991 for 36 hours; melanoma cells treated by Doxorubicin (DXR)  at 0.5 μM is included as a control.

     

     

    Dr. Gao Zhang of University of Pennsylvania. Palbociclib (PD-0332991) HCl purchased from Selleck.

    Serum-deprived T98G glioma cells are restimulated with serum(FBS) with or without 1 μΜ PD-0332991.

     

     

    Dr. Sabine Paternot and Dr Pierre Roger of IRIBHM, ULB, Brussels. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • P16INK4A knockdown in INK4A/ARF-wt human glioma cell LN319 potentiates PDGF-Apromoted anchorage-dependent growth in vitro. Soft agar growth of Ink4a/Arf-deficient mAst and LN444 cells treated with PD0332991. (A) IB analysis. (B) Quantification of soft agar assays. β-actin was used as a loading control in all IB experiments. Data are presented as mean ± s.d. and representative of two independent experiments. **, P < 0.01; ***, P < 0.001

    Dr. Kun-Wei Liu from University of Pittsburgh. Palbociclib (PD-0332991) HCl purchased from Selleck.

製品安全説明書

CDK阻害剤の選択性比較

生物活性

製品説明 Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.
特性 Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).
ターゲット
CDK4/CyclinD3 [1]
(Cell-free assay)
CDK4/CyclinD1 [1]
(Cell-free assay)
CDK6/CyclinD2 [1]
(Cell-free assay)
9 nM 11 nM 15 nM
体外試験

PD 0332991 has little effect on other protein kinases including EGFR, FGFR, PGFR, IR. PD 0332991 is a non-ATP competitive inhibitor of Cdk4. PD 0332991 inhibits MDA-MB-435 breast carcinoma cells with IC50 of 66 nM, which is due to reduced Rb phosphorylation at Ser780. PD 0332991 inhibits thymidine incorporation into the DNA of Rb-positive human breast, colon, and lung carcinomas as well as human leukemias, with IC50 values ranging from 0.04-0.17 μM. PD 0332991 shows no activity in Rb-negative cells. PD 0332991 causes an accumulation of cells in G1 in MDA-MB-453 breast and Colo-205 carcinoma cells. [1] PD 0332991 also shows activity in 5T33MM myeloma cells (immunocompetent model) and sensitizes the cells to killing by bortezomib. [2] PD 0332991 inhibits luminal ER-positive as well as HER2-amplified breast cancer cell lines including MDA-MB-175, ZR-75-30, CAMA-1, MDA-MB-134, HCC-202 and UACC-893. PD 0332991 enhances the activity of tamoxifen and trastuzumab in these cell lines. PD 0332991 enhances the sensitivity of tamoxifen in the MCF7 tamoxifen-resistant cells. [3] A recent study shows that PD 0332991 could suppress malignant rhabdoid tumor (MRT) cell lines including MP-MRT-AN, KP-MRT-RY, G401, KP-MRT-NS and the sensitivity of the MRT cell lines to PD 0332991 is inversely correlated with expression of p16. [4]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MOLM13 MmXxT4lv[XOnIFHzd4F6 MYeyOEBp Mm\UTY5pcWKrdHnvckBw\iCFRFu0JIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gVoIheGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iByLkCwNkDPxE1? MXyyOFY1OTFyMx?=
COLO205 NFLyO3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWW3NkBp NGT1cIVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3Onc4Pl[EBieyCrbnPvdpBwemG2aX;uJI9nKFt|SG30bJlucWSrbnWgbY51dyCGTlGge4l1cCCLQ{WwJI9nKDBwMEO2JO69VQ>? MoTLNlQ3PDFzMEO=
U937 NVHl[3hST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\GcWJVPzJiaB?= MXzBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5Nme3OnZDDhd{BqdmOxcoDvdoF1cW:wIH;mJHs{UF22aIntbYRqdmViaX70c{BFVkFid3n0bEBKSzVyIH;mJFAvOTRizszN M3TIR|I1PjRzMUCz
MOLM13 Mnj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfjbmxpPzJiaB?= NETGW5dCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3PUG0yOyClZXzsd{Bp[XKkb4LpcochTkyWMzDJWGQhdXW2YX70JIF{e2W|c3XkJIF{KGmwY3;ydI9z[XSrb36gc4YhYzOKXYTofY1q\GmwZTDpcpRwKESQQTD3bZRpKEmFNUCgc4YhOC5yOU[g{txO Mn3SNlQ3PDFzMEO=
MOLM13 NV\LZYFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTvNoE4OiCq MYnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IIPvdoFn\W6rYj3y[ZNqe3SjboSgbJVu[W5iTV;MUVE{KGOnbHzzJIF{e2W|c3XkJIF{KGmwY3;ydI9z[XSrb36gc4YhYzOKXYTofY1q\GmwZTDpcpRwKESQQTD3bZRpKEmFNUCgc4YhOC5yOU[g{txO MYKyOFY1OTFyMx?=
MDA-MB-435 NFXMRpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;3TIEzPCCq MYrJR|UxRTBwMU[g{txO NYfIO2F5OTV6MEG4N|E>
K562 MlTRR5l1d3SxeHnjJGF{e2G7 MX[5OkBp NIi0c2xFVVOR Mk\yTWM2OD1{IN88US=> NVvkR5BGOjR2MUe1OlY>
DU145 MV3DfZRwfG:6aXOgRZN{[Xl? MUW5OkBp M1W1OmROW09? NG\QbWhKSzVyPUeuOUDPxE1? NI\3OmszPDRzN{W2Oi=>
MDA-MB-231 NXHzUppuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV[xJO69VQ>? NGPle5czPCCq MUDEUXNQ MoTlR4VtdCCleXPs[UBienKnc4SgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIHH0JGcyKHCqYYPl M1vBUFI1PDF5NU[2
MCF7 NWWwe4NYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnP6NUDPxE1? MnniNlQhcA>? MofSSG1UVw>? M{O4TWNmdGxiY4njcIUh[XK{ZYP0JIF{e2W|c3XkJIF{KGGlY4XteYxifGmxbjDheEBIOSCyaHHz[S=> MkPzNlQ1OTd3Nk[=
MCF7 MmHCT4lv[XOnIFHzd4F6 MX[1JO69VQ>? NFfENFczPCCq M4e3U2ROW09? NVPIdo5vUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBETEt2L3P5Z4xqdkRzIHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZicnX0bY5w[myjc4TvcYEheGixc4Doc5J6dGG2aX;uJIF1KFOncke4NC=> MV2yOFQyPzV4Nh?=
MDA-MB-231 NX;jd2Z1U2mwYYPlJGF{e2G7 M1nRcVUh|ryP M4\We|I1KGh? MlnRSG1UVw>? NEDZSlFKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JGNFUzRxY4njcIlvTDFiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC{ZYTpco9jdGG|dH;tZUBxcG:|cHjvdplt[XSrb36gZZQhW2W{N{iw NE\UWYIzPDRzN{W2Oi=>
MDA-MB-231 MYPGeY5kfGmxbjDBd5NigQ>? MVWxMVExKM7:TR?= MnHZNlQhcA>? M3TSbWROW09? Mofz[I9meyCwb4SgbY5lfWOnIHHwc5B1d3OrczDhd5Nme3OnZDDhd{BRSVKSIHPs[YF3[Wen MkPwNlQ1OTd3Nk[=
MCF7 NVrVVppETnWwY4Tpc44hSXO|YYm= MVuxMVExKM7:TR?= NFPYUogzPCCq M3;sN2ROW09? NXjjVFJs\G:nczDuc5QhcW6mdXPlJIFxd3C2b4Ppd{Bie3Onc4Pl[EBieyCSQWLQJINt\WG4YXfl MWSyOFQyPzV4Nh?=
MDA-MB-231 NVjhWoU5TnWwY4Tpc44hSXO|YYm= NXXaXmxYOC53LUGg{txO MlPlOFghcA>? NVXzXYJ4TE2VTx?= MXLoZZMhdm9iQ3XscEBkgWOuZTDhdpJme3RiYYPz[ZN{\WRiYYOgZYNkfW23bHH0bY9vKGG2IIP1Zk1IOSCyaHHz[S=> MW[yOFQyPzV4Nh?=
MCF7 Mn7NSpVv[3Srb36gRZN{[Xl? MXWwMlUuOSEQvF2= M1HXZ|Q5KGh? NYm5cGVbTE2VTx?= M2jIc4hieyCwbzDD[YxtKGO7Y3zlJIFzemW|dDDhd5Nme3OnZDDhd{Bi[2O3bYXsZZRqd25iYYSgd5VjNUdzIIDoZZNm M4rGfVI1PDF5NU[2
697 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1ztXmlEPTB;MUS4MlM5KG6P NHjLO|dUSU6JRWK=
P12-ICHIKAWA MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLBTWM2OD17Nj6wOEBvVQ>? MWfTRW5ITVJ?
NB69 M{XVSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;aTWM2OD1zNkGuPEBvVQ>? Mkf3V2FPT0WU
EoL-1 NF;1OZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nXO2lEPTB;MUi3MlI3KG6P M3vCTXNCVkeHUh?=
BHT-101 NIXwbZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnvRndkUUN3ME2xPVgvOjVibl2= NEPrS4VUSU6JRWK=
SK-NEP-1 M2\qdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoSwTWM2OD1{MkCuNFIhdk1? MWXTRW5ITVJ?
MHH-NB-11 NVOzbFZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTJ{MD6xPUBvVQ>? NVvORmZyW0GQR1XS
AsPC-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTJ3Mj61N{BvVQ>? NXrmbXRLW0GQR1XS
ES1 NV:yWHB[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTJ3Nj6yOUBvVQ>? NVfpNZlHW0GQR1XS
LAMA-84 MnXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LrTWlEPTB;MkW4MlE6KG6P NHLwZ2pUSU6JRWK=
MOLT-16 NVLzOJJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHTWWt{UUN3ME2yOVgvPDlibl2= M3PhcHNCVkeHUh?=
ES7 NGCwdWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDpSZRSUUN3ME2yO|MvODlibl2= M4X3WHNCVkeHUh?=
KY821 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV65VYdZUUN3ME2zNVQvOSCwTR?= MWjTRW5ITVJ?
RT-112 NHH4[5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fXVWlEPTB;M{KxMlA2KG6P NFvUd2ZUSU6JRWK=
HL-60 M{Tv[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX30eI4zUUN3ME2zOFAvPjZibl2= NHHv[5lUSU6JRWK=
MOLT-4 NVjqZ3V3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\peWlEPTB;M{S1MlE{KG6P MmfBV2FPT0WU
KARPAS-45 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTN5Nj6xOkBvVQ>? M3nhfXNCVkeHUh?=
SK-N-AS M1r4eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnQdZdKSzVyPUO4O{45OyCwTR?= MlzhV2FPT0WU
CTB-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XVbGlEPTB;NEC1MlAzKG6P NVSyNI5[W0GQR1XS
NKM-1 NV71Tlh1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XiWWlEPTB;NEGxMlg6KG6P NIjUN3dUSU6JRWK=
HTC-C3 NX3sTYU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLlSo9nUUN3ME20N|IvQTVibl2= Ml3TV2FPT0WU
BE-13 NXy1VpZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITxd3VKSzVyPUS0OE4zPyCwTR?= M4j3[3NCVkeHUh?=
KOSC-2 MoXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTR4Nj65JI5O NFTFXI5USU6JRWK=
NB14 NY\nOlRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV:xXW9sUUN3ME20PFMvPThibl2= MXvTRW5ITVJ?
CAL-27 MkXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDNTWM2OD12OUSuOVkhdk1? M4DTd3NCVkeHUh?=
H9 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX30eWR4UUN3ME20PVUvPDNibl2= M2fCUXNCVkeHUh?=
RS4-11 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jLeWlEPTB;NUC0Mlc{KG6P NYnNVVZmW0GQR1XS
PA-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXv2WIFpUUN3ME21NFkvQDZibl2= NFyxcFdUSU6JRWK=
MV-4-11 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvJTWM2OD13MUOuPFUhdk1? M13t[XNCVkeHUh?=
OS-RC-2 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;0TWM2OD13MkGuOlIhdk1? MUTTRW5ITVJ?
RPMI-8226 M2\VWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTVfYJ3UUN3ME21NlYvQDZibl2= MXrTRW5ITVJ?
HGC-27 M32xcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTV4ND65PUBvVQ>? MWfTRW5ITVJ?
CHP-212 MoDDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1joS2lEPTB;NUmzMlU6KG6P MX;TRW5ITVJ?
NB10 NV3XT2dVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{T3V2lEPTB;NUm5MlE5KG6P M2DRVXNCVkeHUh?=
HH M3LZSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlW4TWM2OD13OUmuOFMhdk1? MUHTRW5ITVJ?
EW-16 NVfGUW5uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;6TWM2OD14MEOuOVIhdk1? NHvxcm1USU6JRWK=
ES8 NWPhdIFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DHZ2lEPTB;NkC1MlIyKG6P MmXzV2FPT0WU
HAL-01 NELXb5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHVTWM2OD14MEWuOlchdk1? M1LUZ3NCVkeHUh?=
A204 Mle1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDBN3dKSzVyPU[zN{46OSCwTR?= NYfhZXVyW0GQR1XS
MHH-PREB-1 NVjyPY1MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm[4TWM2OD14M{[uPVkhdk1? MWXTRW5ITVJ?
EM-2 MmPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fKb2lEPTB;NkWwMlY1KG6P NUXhZYpzW0GQR1XS
BV-173 M364[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFP4UmhKSzVyPU[1Nk41QCCwTR?= NHnMVFZUSU6JRWK=
ONS-76 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTZ5Nz64NkBvVQ>? NGC5UXdUSU6JRWK=
KM-H2 NULJ[XQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLkOYR4UUN3ME22PVUvPTRibl2= NIfTd|dUSU6JRWK=
D-263MG NHnwfVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jyOWlEPTB;N{G3MlEzKG6P Ml[xV2FPT0WU
ES3 NFL6WnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXw[FZuUUN3ME23NlgvQTNibl2= Ml\0V2FPT0WU
VA-ES-BJ MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTd|Mj6yO{BvVQ>? MWfTRW5ITVJ?
NBsusSR NEm3SlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTd2Mj65PUBvVQ>? M3jUSHNCVkeHUh?=
NCI-H520 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkH5TWM2OD15NE[uOVIhdk1? NFT4WItUSU6JRWK=
ES5 M4PYNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTd3Mj64JI5O M{fqNnNCVkeHUh?=
T-24 NIjrb29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrITpdKSzVyPUe3PE44OSCwTR?= M2LifnNCVkeHUh?=
SW962 MlPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRThyOD62N{BvVQ>? M4P2ZnNCVkeHUh?=
EW-3 M4jCRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17Ve2lEPTB;OEC4Mlc3KG6P M1K0SnNCVkeHUh?=
RXF393 NFLGXVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{[2T2lEPTB;OEGyMlc6KG6P MmfKV2FPT0WU
U251 M{S5PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH[3[pdKSzVyPUixN{45QCCwTR?= MYjTRW5ITVJ?
CAMA-1 MlHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrafIxKSzVyPUizN{46PCCwTR?= MmXoV2FPT0WU
JVM-3 M4Wxcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIqxSHZKSzVyPUi1NU44QCCwTR?= MVjTRW5ITVJ?
COLO-800 NFTNeGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DqZmlEPTB;OEm3Mlc5KG6P NYf4T3A6W0GQR1XS
OVCAR-5 NYTYXXNsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFP5fXpKSzVyPUmwNE4yKG6P M3S1VnNCVkeHUh?=
LB1047-RCC M2PScmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTl{Nz61OkBvVQ>? MXPTRW5ITVJ?
SW954 M3zqbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoL1TWM2OD17MkmuOFEhdk1? M1r1c3NCVkeHUh?=
J-RT3-T3-5 M3j4UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\BTWM2OD17M{[uNFYhdk1? MnSwV2FPT0WU
Mewo MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTl|Nj62JI5O MYXTRW5ITVJ?
NCI-H1770 NEXZXolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnK0TWM2OD17NECuOVUhdk1? NHHNR5FUSU6JRWK=
HO-1-N-1 MnHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETUN|JKSzVyPUm2Nk45OSCwTR?= Mlu5V2FPT0WU
HSC-3 M3\1Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo[3TWM2OD17Nk[uOFghdk1? NUC1S4hSW0GQR1XS
TYK-nu M2jNZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTl7OD6yOUBvVQ>? NEfDR4FUSU6JRWK=
KYSE-150 M4K5ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfDcJd6UUN3ME2xMlAxODd4IN88US=> MYHTRW5ITVJ?
SN12C MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XpdGlEPTB;MT6wNFg4PSEQvF2= MVHTRW5ITVJ?
MOLT-13 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4KxUmlEPTB;MT6wNVQzOSEQvF2= M2\xOnNCVkeHUh?=
TE-11 MnXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fsO2lEPTB;MT6wOFgyOiEQvF2= M1fPSXNCVkeHUh?=
DB MknlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17jUGlEPTB;MT6wO|I4OyEQvF2= MXLTRW5ITVJ?
CAL-39 NVexXW8zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPHVJhNUUN3ME2xMlA4PTJ{IN88US=> NXL1WHFPW0GQR1XS
A3-KAW NH3EWlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVezNJRMUUN3ME2xMlA5PDB6IN88US=> NIXtSXBUSU6JRWK=
CHP-134 M3HPbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;wdGlEPTB;MT6xNVgxPyEQvF2= NUPhV2plW0GQR1XS
TGW NGjIZmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHMTWM2OD1zLkGyN|k2KM7:TR?= M{jacHNCVkeHUh?=
QIMR-WIL MnPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjoZXdKSzVyPUGuNVMyOzRizszN NWL6OZdNW0GQR1XS
NCI-SNU-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLFfJFTUUN3ME2xMlE3OzV2IN88US=> Ml3hV2FPT0WU
CGTH-W-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTITWM2OD1zLkG3NVg3KM7:TR?= M3zQcnNCVkeHUh?=
MHH-ES-1 NWO0fmVbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoX2TWM2OD1zLkG3PVg3KM7:TR?= M4nybHNCVkeHUh?=
LB2241-RCC MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13nO2lEPTB;MT6xPFYzKM7:TR?= NGixNZZUSU6JRWK=
ML-2 NVWwSIZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3E[4tKUUN3ME2xMlIxPzN2IN88US=> Ml;JV2FPT0WU
COR-L23 NX\pN|dPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrDSphmUUN3ME2xMlIzQTN|IN88US=> NHTpOXdUSU6JRWK=
BFTC-905 MoC5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTFwMkSyOlch|ryP NY[zSmI1W0GQR1XS
Hs-578-T Mn;iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XMXWlEPTB;MT6yOVgyPyEQvF2= M1H1WnNCVkeHUh?=
KG-1 NGfWOpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFH2VWJKSzVyPUGuNlY3QDZizszN M4n4eXNCVkeHUh?=
HEL M{G5R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jvdGlEPTB;MT6yPVM{QCEQvF2= NIXERohUSU6JRWK=
A549 NHLVW4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1P2T2lEPTB;MT6yPVM6QSEQvF2= MoC2V2FPT0WU
COLO-741 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;RTWM2OD1zLkOyNFg6KM7:TR?= MoXnV2FPT0WU
PC-3 MknvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnEZm53UUN3ME2xMlM2OjJzIN88US=> NVHHOm9tW0GQR1XS
HOS M2rnfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1L1c2lEPTB;MT6zOVI6PiEQvF2= MWrTRW5ITVJ?
HT-1080 NE[4SYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1ew[GlEPTB;MT6zO|UyQSEQvF2= NHnCSHhUSU6JRWK=
TE-8 NFfEVZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTFwNEG3O|Qh|ryP MWnTRW5ITVJ?
BHY M2PQeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvSRZhKSzVyPUGuOFY6OjNizszN NELXNWRUSU6JRWK=
BB65-RCC MkDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LEZ2lEPTB;MT61NFUzQCEQvF2= MmK0V2FPT0WU
HN MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlmzTWM2OD1zLkW0NFcyKM7:TR?= M1zrS3NCVkeHUh?=
NCI-H441 MmHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFf2PHBKSzVyPUGuOVQ6ODdizszN M1LOT3NCVkeHUh?=
RPMI-8866 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2G5UmlEPTB;MT61PFUxPyEQvF2= M1PzfnNCVkeHUh?=
CAL-62 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTFwNkC4OlIh|ryP MkHKV2FPT0WU
MG-63 NEfST4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\mT3RJUUN3ME2xMlYyQDF|IN88US=> MoPiV2FPT0WU
SK-LU-1 MnvvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnRTWM2OD1zLk[yNVUzKM7:TR?= M1XORXNCVkeHUh?=
BCPAP MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfJb4I3UUN3ME2xMlY3PDV5IN88US=> MmjHV2FPT0WU
22RV1 NIf2NXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTFwNke4OFMh|ryP NYjFTlVKW0GQR1XS
T47D MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TiSmlEPTB;MT62PFA3OSEQvF2= Ml3EV2FPT0WU
MSTO-211H MkPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLoTlJsUUN3ME2xMlY6PjB|IN88US=> NGTYc4NUSU6JRWK=
DEL NYjnZ2VXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXqTWM2OD1zLkewNlc{KM7:TR?= NF\ISJJUSU6JRWK=
H4 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HuRmlEPTB;MT63N|IyOiEQvF2= NInZTmhUSU6JRWK=
CAL-51 Mkm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVH4fYpwUUN3ME2xMlc1QDV3IN88US=> NET3fmJUSU6JRWK=
ABC-1 M2n3OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjqT4lGUUN3ME2xMlc5PTh{IN88US=> NUPXTG1qW0GQR1XS
MZ2-MEL M1P2TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1n4UmlEPTB;MT63PVU1OiEQvF2= M2HYb3NCVkeHUh?=
YKG-1 MnzoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTFwOEGwOlEh|ryP MWjTRW5ITVJ?
KM12 NYmyRllST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTFwOEG2NFIh|ryP NFO2TY1USU6JRWK=
L-363 Moj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTFwOEe0NVIh|ryP MmP0V2FPT0WU
KU812 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvyTWM2OD1zLki5NlgzKM7:TR?= M4nSVHNCVkeHUh?=
LOXIMVI NUD5PJRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fnW2lEPTB;MT65NVIzQCEQvF2= MoSwV2FPT0WU
G-401 M3u3RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTtTWM2OD1zLkmyOFI5KM7:TR?= NEnqdHNUSU6JRWK=
SW780 NUPlUmt3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfGTWM2OD1zLkm2NlQ3KM7:TR?= NFnQbIpUSU6JRWK=
SW872 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPFTWM2OD1zLkm4N|Mh|ryP MlHrV2FPT0WU
NB7 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfVd2tKSzVyPUGuPVk{OjNizszN NGPtNpJUSU6JRWK=
T98G M4nGVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzobW4yUUN3ME2yMlAxPjZ4IN88US=> M4TCTXNCVkeHUh?=
SW1710 MlXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjiTYo2UUN3ME2yMlA3QTR3IN88US=> NXP1Rm17W0GQR1XS
NCI-H1573 M2TxRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTyTWM2OD1{LkC3Nlk5KM7:TR?= MUjTRW5ITVJ?
KE-37 NHrvRlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPOTWM2OD1{LkC4PVUyKM7:TR?= NHPZN2tUSU6JRWK=
786-0 MoH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTJwMUW0N|kh|ryP MVLTRW5ITVJ?
SAS MmXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXxZ2NKSzVyPUKuNlA{PzRizszN MWHTRW5ITVJ?
CAL-54 NFLlNJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIf0TFBKSzVyPUKuNlA1OTNizszN NHzifG9USU6JRWK=
SF268 MmnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIX5TnZKSzVyPUKuNlMyOjJizszN NIDPTHZUSU6JRWK=
SW620 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fmPGlEPTB;Mj6yOlE3QSEQvF2= NED5SYdUSU6JRWK=
MN-60 NVW4cWNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnXTYlKSzVyPUKuN|ExPiEQvF2= NH\aO4NUSU6JRWK=
EFO-27 NYmyboxwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTJwM{KwOVgh|ryP Ml\tV2FPT0WU
NCI-H747 M3fJXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrPb|JKSzVyPUKuN|IyQTlizszN MVHTRW5ITVJ?
HCC2218 NFTLS4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHmXpdzUUN3ME2yMlM2Ozd2IN88US=> NHvqdXBUSU6JRWK=
MIA-PaCa-2 Ml[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTJwM{[0N|ch|ryP MULTRW5ITVJ?
SJSA-1 NWm5eVEzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moe2TWM2OD1{LkO3O|k3KM7:TR?= M1TGZnNCVkeHUh?=
RKO MkPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYr6bnV1UUN3ME2yMlM5PDl4IN88US=> M2fp[3NCVkeHUh?=
NB6 NEn5[5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37xOmlEPTB;Mj60NFM4PCEQvF2= NGXBcnVUSU6JRWK=
ES4 M3:5Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13qR2lEPTB;Mj60OVQzOiEQvF2= M3TLUnNCVkeHUh?=
EGI-1 Mnn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTJwNE[4PFMh|ryP NIjU[HhUSU6JRWK=
CTV-1 M3\xc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HHZmlEPTB;Mj61Nlc4OyEQvF2= NWTW[XJnW0GQR1XS
NCI-H1355 NW\2bnN{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1H0TmlEPTB;Mj61OVk2OSEQvF2= MnXlV2FPT0WU
GT3TKB MkXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTJwNUmxPVkh|ryP Mn\UV2FPT0WU
SK-HEP-1 NHnCUJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTJwNUmyOlYh|ryP MljpV2FPT0WU
GAMG NUP3U2I2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfNOmJKSzVyPUKuOVk{QTRizszN MkjmV2FPT0WU
SK-MES-1 MofrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXXTWM2OD1{Lk[xPFA{KM7:TR?= MnjyV2FPT0WU
RO82-W-1 NGX6VnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLqdGxKUUN3ME2yMlYzODV5IN88US=> NUGyfGxNW0GQR1XS
ECC10 NFT3UW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYruWJBbUUN3ME2yMlcxOjB4IN88US=> MlW0V2FPT0WU
MCF7 NHG4XVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTJwN{G0OlQh|ryP MWPTRW5ITVJ?
D-283MED NUHGN2VGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PlZWlEPTB;Mj63NlQ{KM7:TR?= NYHPN41pW0GQR1XS
RPMI-7951 M3G4dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7CTWM2OD1{Lke1Olk1KM7:TR?= M2PJOnNCVkeHUh?=
Ramos-2G6-4C10 NHj3em5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDrVm95UUN3ME2yMlc4ODl7IN88US=> M1XIVnNCVkeHUh?=
KGN NYPpSZhST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPaTWM2OD1{LkixPFg1KM7:TR?= MXjTRW5ITVJ?
NUGC-3 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\YTWM2OD1{LkiyOVA2KM7:TR?= NWLN[ZNOW0GQR1XS
NCI-H292 M4Pzfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3raZWlEPTB;Mj64OVA2OyEQvF2= NU\oSXhnW0GQR1XS
Becker MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\aO|hUUUN3ME2yMlk2QDN{IN88US=> M4XZbXNCVkeHUh?=
NCI-H1299 M{XkfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTNwMEWyOlMh|ryP MnX5V2FPT0WU
ETK-1 M3PkXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFq5VnlKSzVyPUOuNFU1OyEQvF2= NWfRXHVbW0GQR1XS
TK10 NWrJZ3h2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTNwMkCxOlUh|ryP M3LkUHNCVkeHUh?=
VMRC-RCZ MkDGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUG0SY9uUUN3ME2zMlM3PDh6IN88US=> MXHTRW5ITVJ?
YH-13 MljaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLENmNKSzVyPUOuOFQxPzlizszN MXfTRW5ITVJ?
DU-145 MlHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWP4PWNjUUN3ME2zMlQ3OjZ7IN88US=> MYjTRW5ITVJ?
SW1088 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\aWWhKSzVyPUOuOFc1PyEQvF2= MoDZV2FPT0WU
HOP-92 M2\qVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIi2OmhKSzVyPUOuOVA{PDJizszN NXPtfFZbW0GQR1XS
KP-N-YS M3XlTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFKybmJKSzVyPUOuOlIyOzlizszN MUHTRW5ITVJ?
NCI-H460 M4TpfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELze4JKSzVyPUOuOlY4OyEQvF2= NI\0[JFUSU6JRWK=
U-2-OS MoX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTNwN{K1N|Uh|ryP NHjMPHdUSU6JRWK=
A101D NFqzTohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTNwN{[5N|Yh|ryP NILISndUSU6JRWK=
MDA-MB-231 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnVUINKSzVyPUOuPFE6PTFizszN MmHOV2FPT0WU
IST-MES1 M4Lv[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTNwOEOyJO69VQ>? M{[we3NCVkeHUh?=
COR-L105 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHvTWM2OD12LkCxPEDPxE1? NHnSU5BUSU6JRWK=
NCI-H1437 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vLTGlEPTB;ND6wNlMxOiEQvF2= MkXjV2FPT0WU
CAL-85-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITLTpNKSzVyPUSuNFI1PjFizszN NX;COFNxW0GQR1XS
MZ1-PC NVvQU5h[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTRwMUi1OVYh|ryP NFznUVlUSU6JRWK=
VM-CUB-1 MmX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\GZ2lEPTB;ND6zNVI5PCEQvF2= MVTTRW5ITVJ?
CHL-1 MmK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXxRZRlUUN3ME20MlMzOTZ7IN88US=> NWjtUmhuW0GQR1XS
MDA-MB-361 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjyS5VKSzVyPUSuN|MyPTNizszN NVvlNo5YW0GQR1XS
NCI-H661 Mkn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvTTWM2OD12LkWwNFkzKM7:TR?= MVTTRW5ITVJ?
EW-11 M{jU[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTRwNUKyN|Eh|ryP MX3TRW5ITVJ?
BEN M2S1UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYe4RpZGUUN3ME20MlUzQDF3IN88US=> NF3BS4NUSU6JRWK=
BFTC-909 NEDJXINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTRwNU[yO|Uh|ryP NUi1V3RuW0GQR1XS
NCI-H2087 NU[wU|BmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYT1TmV3UUN3ME20MlU5OTZ2IN88US=> Ml7CV2FPT0WU
RVH-421 NFexS2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDWSIFDUUN3ME20MlY3PjlizszN MYjTRW5ITVJ?
P30-OHK NITuN5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTETZdpUUN3ME20MlY5ODB6IN88US=> MoPyV2FPT0WU
NCI-H28 Mof4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoS3TWM2OD12LkixOlYyKM7:TR?= M3;wbXNCVkeHUh?=
ES6 M2\IN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfkTWM2OD12LkizNFE3KM7:TR?= NIPwdGhUSU6JRWK=
769-P MnvaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4n1bWlEPTB;ND64OVkzPiEQvF2= M3SwRnNCVkeHUh?=
OE33 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTRwOEixOlEh|ryP NYTNSWZYW0GQR1XS
SW982 NIDNe5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrxTXFLUUN3ME20Mlk2ODZzIN88US=> M4PaVHNCVkeHUh?=
A388 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7LTWM2OD13LkCyPVg{KM7:TR?= M1TnUnNCVkeHUh?=
TI-73 NE\wOFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3aTWM2OD13LkC2NVk1KM7:TR?= MnjCV2FPT0WU
HCT-116 M1rBVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPZOodiUUN3ME21MlA6QDh7IN88US=> NETkZYxUSU6JRWK=
HuP-T3 Mo\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnX1TWM2OD13LkG4O|A6KM7:TR?= NWLCVohuW0GQR1XS
G-402 NUnTeIRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDRVIhFUUN3ME21MlE6PDF4IN88US=> NEHoR4JUSU6JRWK=
NCI-H1792 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmj6TWM2OD13LkK0OlIzKM7:TR?= NITEOGVUSU6JRWK=
NCI-H209 NXXUV4NqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFG5dWlKSzVyPUWuNlU6PDJizszN MkKyV2FPT0WU
NCI-H1650 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnrTndKSzVyPUWuN|A3OzRizszN NF6zTWVUSU6JRWK=
LCLC-97TM1 NHnKfYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHQcmRKSzVyPUWuN|E5ODhizszN NGLH[JpUSU6JRWK=
S-117 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHlPFdXUUN3ME21MlM3QTd4IN88US=> M2fTcXNCVkeHUh?=
GI-ME-N NXXaXYJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmL0TWM2OD13LkO5OlgyKM7:TR?= NYq4b5pkW0GQR1XS
NCI-H2122 NFTrfpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHBTWM2OD13LkS5N|k4KM7:TR?= MYPTRW5ITVJ?
NCI-H1793 NGj6ZmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DLUmlEPTB;NT62O|U6OyEQvF2= NGXNT|lUSU6JRWK=
C2BBe1 MneyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLZTWM2OD13LkewNFg5KM7:TR?= MWjTRW5ITVJ?
TE-12 NWTRNXFXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jobWlEPTB;NT64NFU2PiEQvF2= Mn30V2FPT0WU
LCLC-103H NWXoWlAzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTVwOUG3JO69VQ>? MXfTRW5ITVJ?
A673 NIPwRWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITDWpJKSzVyPUWuPVE6OzJizszN NVHuNnRlW0GQR1XS
BB30-HNC NX\hT49CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLrfVVKSzVyPUWuPVg{PiEQvF2= NYe1b4p[W0GQR1XS
SF295 MofmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfvfWNiUUN3ME22MlAxPDJ{IN88US=> MojQV2FPT0WU
KU-19-19 NITr[2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTZwMEG3N|Eh|ryP MoHjV2FPT0WU
CFPAC-1 MnvnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLzTWM2OD14LkC0OFQ{KM7:TR?= MnTYV2FPT0WU
LoVo MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTiTWM2OD14LkC1NFY{KM7:TR?= NX;SfFFoW0GQR1XS
8505C NGLWPHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLxRXh{UUN3ME22MlA4PTd|IN88US=> MVXTRW5ITVJ?
GMS-10 NV;wXXZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoP1TWM2OD14LkG1NFAzKM7:TR?= NIfvbYJUSU6JRWK=
Ca9-22 NVjsPZB1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvqeph[UUN3ME22MlE3PzFizszN NHXnPFBUSU6JRWK=
DOK MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfrZlVKSzVyPU[uNlIxPzJizszN M2\3UXNCVkeHUh?=
FADU MnvrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTZwMk[wN|kh|ryP MXvTRW5ITVJ?
BxPC-3 MkPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnXT3pKSzVyPU[uNlc{OiEQvF2= MXLTRW5ITVJ?
CAL-33 M13ac2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTZwMkmyNFEh|ryP NY\D[pdwW0GQR1XS
SHP-77 M1H0fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLmTWM2OD14LkOxOVEzKM7:TR?= NGjOWJFUSU6JRWK=
LXF-289 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HrcGlEPTB;Nj6zN|Q2PSEQvF2= MXjTRW5ITVJ?
GB-1 MmTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYG1RmJkUUN3ME22MlM5OiEQvF2= NEn6VXBUSU6JRWK=
KS-1 MnnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfqdnBOUUN3ME22MlM5PDR5IN88US=> MmC1V2FPT0WU
D-502MG M{\6V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTZwNEKzO|Yh|ryP NVHtN5c3W0GQR1XS
LAN-6 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXSTWM2OD14LkWxNFI{KM7:TR?= M2XGcHNCVkeHUh?=
H-EMC-SS NV3jVHNsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFz6SnBKSzVyPU[uOVYyPDdizszN NEDkOHZUSU6JRWK=
LC-2-ad NX3m[mt1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnDTWM2OD14Lk[wNFc3KM7:TR?= NW\mRXB[W0GQR1XS
NCI-H1693 NYXjS4g3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLCTWM2OD14Lk[yNlE2KM7:TR?= MYjTRW5ITVJ?
SK-N-FI M3LH[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3[wc2lEPTB;Nj63OVA1PCEQvF2= M{XZSnNCVkeHUh?=
D-423MG MoH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\QTWM2OD14Lke2NVE4KM7:TR?= NG\3fWpUSU6JRWK=
KNS-42 NIW0T5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzVSZRbUUN3ME22Mlc5OTl5IN88US=> NV34fmw1W0GQR1XS
GCT NWe4VlNKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\aNWlEPTB;Nj65N|gh|ryP NIm1OYdUSU6JRWK=
DSH1 NH3BPZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXMTWM2OD15LkC2N|Mh|ryP MoHHV2FPT0WU
D-247MG M3LzOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvNXmlwUUN3ME23MlA4QDhzIN88US=> Ml7xV2FPT0WU
NCI-SNU-5 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLRTWM2OD15LkG4N|cyKM7:TR?= M1K3cXNCVkeHUh?=
TE-6 NIXFVolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUCxeI1IUUN3ME23MlIxPjBzIN88US=> M4[5dXNCVkeHUh?=
NOMO-1 NVvufnkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moi3TWM2OD15LkKyNVI4KM7:TR?= NVm3[5p1W0GQR1XS
NB17 Mn;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvITWM2OD15LkOwN|A6KM7:TR?= MnHnV2FPT0WU
EW-22 MnO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTdwM{SzOFgh|ryP MUPTRW5ITVJ?
EW-13 NUfLZ|B2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTdwM{WxOlIh|ryP M{LqRnNCVkeHUh?=
DOHH-2 M124[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLlTWM2OD15LkS0NFIh|ryP MmTUV2FPT0WU
TGBC1TKB NFTHdnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojRTWM2OD15LkS5PFk6KM7:TR?= NVLVWYhrW0GQR1XS
GR-ST MonmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGr2TldKSzVyPUeuOVI2QTRizszN M1LW[XNCVkeHUh?=
KYSE-520 NWDUXIU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnQTWM2OD15LkW1OVE2KM7:TR?= M1nrSXNCVkeHUh?=
CAPAN-1 NXfkZ|NDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\NPGlEPTB;Nz61PVUyKM7:TR?= NIH3T3lUSU6JRWK=
HCE-4 M1L6WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrKbVFJUUN3ME23MlYzOjd7IN88US=> M3z2SXNCVkeHUh?=
MLMA M1fo[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPiSItKSzVyPUeuOlI6PTdizszN M4TpUHNCVkeHUh?=
HT-144 NUX5[HhNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTdwNkWzOlgh|ryP MlK2V2FPT0WU
KYSE-180 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\nRoJxUUN3ME23MlcyOTZ7IN88US=> M3Szb3NCVkeHUh?=
TE-5 NYTHRmZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG[xNVFKSzVyPUeuPVU6PzFizszN MV7TRW5ITVJ?
IGROV-1 M4HtfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XHXmlEPTB;Nz65PFU2OSEQvF2= NXK0PHJGW0GQR1XS
NCI-H1581 NUjvOIw1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPMTWM2OD16LkCxNkDPxE1? NUDSdG1OW0GQR1XS
SW1990 MnPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRThwMES2OVkh|ryP MoHOV2FPT0WU
EFM-19 NXm3UlByT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nEe2lEPTB;OD6wPFU1PSEQvF2= MYXTRW5ITVJ?
OGR-1 M1vKUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3rVG1KSzVyPUiuOFMxOjNizszN NV3HV2FVW0GQR1XS
U-118-MG M2TjXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;neXBKSzVyPUiuOFM1PjNizszN NGj4OoRUSU6JRWK=
SK-OV-3 M4ftc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7QTWM2OD16LkS2O|Y2KM7:TR?= MoPWV2FPT0WU
KNS-62 M3XPe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHf0eoxKSzVyPUiuOVE4PjFizszN M2\adXNCVkeHUh?=
GOTO NGjmSGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRThwNUe2N|Uh|ryP M4nnUXNCVkeHUh?=
8305C NWPX[ZBIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPaeYVKSzVyPUiuO|A1QDRizszN MWDTRW5ITVJ?
RPMI-2650 NWXM[lQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1v4fWlEPTB;OD63NVk2PSEQvF2= M13sSHNCVkeHUh?=
NEC8 NEnPdG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRThwN{SzNFch|ryP NYDYZ4RyW0GQR1XS
KYSE-450 NHLRRZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXr0bJdQUUN3ME24Mlg3PTR6IN88US=> MUTTRW5ITVJ?
RMG-I MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjxTWM2OD17LkG0NFU5KM7:TR?= NF3JUXVUSU6JRWK=
CAKI-1 NWr4cJdWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTlwM{G5O|kh|ryP Ml\lV2FPT0WU
KYSE-510 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljrTWM2OD17LkO1O|c5KM7:TR?= NF;rNYhUSU6JRWK=
A4-Fuk M1XJVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUf2WlV4UUN3ME25MlM3PzBzIN88US=> Mn\CV2FPT0WU
AN3-CA M1G5WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLkTWM2OD17LkS1OFQ1KM7:TR?= MUXTRW5ITVJ?
SK-N-DZ M4fvfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVv0e|BLUUN3ME25MlczQDR7IN88US=> NUnXfoc4W0GQR1XS
HSC-2 M3rjbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;lTWM2OD17Lke2OlI6KM7:TR?= NHThdmtUSU6JRWK=
EW-1 M4nD[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTCV2t2UUN3ME25Mlc6OzZ7IN88US=> NVjleHV7W0GQR1XS
D-566MG M3W5PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEP6SW9KSzVyPUmuPFM3PjRizszN NFz6N2dUSU6JRWK=
COLO-792 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzvZos4UUN3ME25Mlk5PzR4IN88US=> MlHBV2FPT0WU
TE-10 M3H4N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTFyLkCzPVYh|ryP NWnEdXlrW0GQR1XS
NCI-H650 NH;nSoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nrUmlEPTB;MUCuOFI5PiEQvF2= NUXSSVNwW0GQR1XS
U-266 MmW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTFyLkS1OUDPxE1? MlHiV2FPT0WU
Detroit562 NUDwTGQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\kOVhKSzVyPUGxMlA2OTVizszN MWXTRW5ITVJ?
NH-12 MlH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjyTWM2OD1zMT6xOFQ3KM7:TR?= MlPkV2FPT0WU
CO-314 NEfPRW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fLbGlEPTB;MUGuNlg1OiEQvF2= M4jkfHNCVkeHUh?=
IST-MEL1 NIG4T5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLWVmt3UUN3ME2xNU42OzJ|IN88US=> MnvjV2FPT0WU
KNS-81-FD NX24d2FMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rIOWlEPTB;MUGuOVUzPyEQvF2= NYLEW2ZOW0GQR1XS
SW1463 NGT0dIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTFzLkW5PFkh|ryP NFvCd2hUSU6JRWK=
NCI-H23 M1rXO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnwTWM2OD1zMT62OVUzKM7:TR?= MXjTRW5ITVJ?
SK-MEL-2 NULLVHR{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4q0TmlEPTB;MUGuO|E6PyEQvF2= NWjLO|U2W0GQR1XS
NB13 MkjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDjTWM2OD1zMj6xOFk2KM7:TR?= M{\kdnNCVkeHUh?=
Daoy MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTF{LkK4OVYh|ryP NVe5VVdPW0GQR1XS
NCI-H1623 Mnr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDZfIlKSzVyPUGyMlM5ODFizszN MmfZV2FPT0WU
NMC-G1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LqNWlEPTB;MUKuO|E4KM7:TR?= NI\4ZlBUSU6JRWK=
DK-MG NUDTNFJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfTTWM2OD1zMj65OFgzKM7:TR?= MnKzV2FPT0WU
TCCSUP NUH3ephUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLYUYpKSzVyPUGzMlEzQDRizszN NVi2fZBWW0GQR1XS
SCC-15 M3nxVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXJZ5dKSzVyPUGzMlI3PTFizszN M2L1ZXNCVkeHUh?=
NOS-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTEOpNKSzVyPUGzMlI5QTNizszN NF\vT3JUSU6JRWK=
RH-1 MnvmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTF|LkOwN|ch|ryP NFK2fIxUSU6JRWK=
SK-MEL-3 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTF|LkO3Nlgh|ryP NXXxeoo1W0GQR1XS
NB5 NGPySVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfiTWM2OD1zMz60NFY4KM7:TR?= NVjpcpBbW0GQR1XS
SNU-387 NH;VcYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTF|LkWwO|Ih|ryP NHrLNmFUSU6JRWK=
CAL-120 NEW0PGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;OTWM2OD1zMz62O|E5KM7:TR?= NEjU[YVUSU6JRWK=
Mo-T MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXFRpBJUUN3ME2xN{44ODdizszN M1TtcXNCVkeHUh?=
LNCaP-Clone-FGC NFHHNJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjDTnZUUUN3ME2xN{44QTl{IN88US=> MWnTRW5ITVJ?
CAN MlvOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEGzcFZKSzVyPUG0MlAzQDhizszN M4LxUHNCVkeHUh?=
SK-MEL-30 NGW4dpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPNUIVtUUN3ME2xOE4xPjNizszN MlPaV2FPT0WU
COLO-678 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;hNWlEPTB;MUSuNFgzOiEQvF2= MV\TRW5ITVJ?
SCC-9 NHH4PINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTF2LkGwNlEh|ryP M3fRSXNCVkeHUh?=
KINGS-1 M4niUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\zTWM2OD1zND6xOFAzKM7:TR?= MVXTRW5ITVJ?
SL-513 M3TEPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4qyfGlEPTB;MUSuNVg4KM7:TR?= MY\TRW5ITVJ?
HLE M1nWR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkSwTWM2OD1zND6zPFUzKM7:TR?= NFPSbFZUSU6JRWK=
SW1573 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHic3JKSzVyPUG0MlQ1OzVizszN M1LxPHNCVkeHUh?=
KYSE-140 M1LjeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFz3eZlKSzVyPUG0MlY{OjdizszN NVTJOpFLW0GQR1XS
SK-PN-DW NFzLdXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7WXlJxUUN3ME2xOE45ODBzIN88US=> M37MeXNCVkeHUh?=
A253 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\UR284UUN3ME2xOU4xPjJ3IN88US=> NGnYZZpUSU6JRWK=
CAL-12T Mm[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\Bc2lEPTB;MUWuOFY3OiEQvF2= NHjHW2RUSU6JRWK=
COLO-679 MnHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4C2[2lEPTB;MUWuO|Y5OyEQvF2= M4PtUXNCVkeHUh?=
UACC-257 NUeycIdvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml76TWM2OD1zNj6xNlAyKM7:TR?= M33lbHNCVkeHUh?=
U-87-MG NEDLfHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTF4LkO1NlMh|ryP NYDUemF7W0GQR1XS
HCC1806 NVzMdWJlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTF4LkewO|Eh|ryP MkS3V2FPT0WU
NCI-H2170 MnSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHhNI9CUUN3ME2xO{4zPDR6IN88US=> NUDTbWVvW0GQR1XS
AGS NWjndFFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzSUHlKSzVyPUG3MlM5ODhizszN Mm\iV2FPT0WU
MEL-HO MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDsXmJFUUN3ME2xO{44PTB|IN88US=> NX;nUXNoW0GQR1XS
SW48 NUDSdoF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTF5Lke3NVYh|ryP NWjhO3ptW0GQR1XS
HuP-T4 M1LMOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrxSmtNUUN3ME2xPE4xOjB4IN88US=> M370XXNCVkeHUh?=
NCI-H720 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHaTWM2OD1zOD6xOFAzKM7:TR?= MUXTRW5ITVJ?
RCC10RGB NIK4WFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHOW5lKSzVyPUG4MlE3QTdizszN NGD5T3BUSU6JRWK=
HD-MY-Z MmLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7nNpBKSzVyPUG4MlIzPTRizszN MX7TRW5ITVJ?
A427 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHCV41KUUN3ME2xPE42ODl2IN88US=> NWLyWZpmW0GQR1XS
HCC2998 MmTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfzTWM2OD1zOD62NFUyKM7:TR?= M2TZbHNCVkeHUh?=
EPLC-272H Ml;jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDGTWM2OD1zOT6wOFM1KM7:TR?= MXLTRW5ITVJ?
C32 NInyV5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX:xXXdCUUN3ME2xPU4xPDVizszN Mn[3V2FPT0WU
UMC-11 NHv5fllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHjTWM2OD1zOT6yNVI{KM7:TR?= MljsV2FPT0WU
CaR-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInGcnZKSzVyPUG5MlY5ODRizszN NEHHRoZUSU6JRWK=
KYSE-410 NX3mb|VVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorSTWM2OD1zOT65NVM6KM7:TR?= MnHjV2FPT0WU
HuCCT1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHMTWM2OD1{MD62Nlk1KM7:TR?= MWPTRW5ITVJ?
LB996-RCC MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYX2S|JQUUN3ME2yNE44OTZ6IN88US=> Ml3VV2FPT0WU
KYSE-70 M3vmWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPoOFR[UUN3ME2yNE45ODV7IN88US=> NXvuOZZXW0GQR1XS
CAL-72 MlnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nvbGlEPTB;MkCuPVE2KM7:TR?= MVrTRW5ITVJ?
Capan-2 MlqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHUW|N1UUN3ME2yNU4xPDF|IN88US=> NXTteWxzW0GQR1XS
PANC-08-13 NW[1PGliT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTJzLkK1NVUh|ryP MVzTRW5ITVJ?
SBC-1 M2f5W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;Jd2lEPTB;MkGuN|A5OSEQvF2= NHLZNVhUSU6JRWK=
MFM-223 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGiyVGJKSzVyPUKxMlM{PDJizszN MV;TRW5ITVJ?
BB49-HNC M1i3d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmL6TWM2OD1{MT61O|E3KM7:TR?= MmK1V2FPT0WU
SH-4 M3mxUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYniXJZDUUN3ME2yNU43PjF6IN88US=> NIj4V4lUSU6JRWK=
HuO9 M2Cze2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHGTWM2OD1{MT65PFI2KM7:TR?= Mn;WV2FPT0WU
AM-38 NULq[ohrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfqTWM2OD1{Mj6wOFg2KM7:TR?= NEL5TGFUSU6JRWK=
A431 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTOPYVTUUN3ME2yN{4zOTF7IN88US=> NUfkWJg2W0GQR1XS
YAPC NXvSSYpJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfjTWM2OD1{Mz6yOlUyKM7:TR?= MVPTRW5ITVJ?
LU-139 M1nPdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPP[HNKSzVyPUKzMlQ5ODlizszN MkPMV2FPT0WU
HEC-1 Mn;2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTJ|LkS5N|ch|ryP M{\WcnNCVkeHUh?=
SCC-25 MkL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXwR29RUUN3ME2yOE4{ODB4IN88US=> NVLLSVBHW0GQR1XS
HT-29 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLrTWM2OD1{ND6zPFI{KM7:TR?= M{PV[3NCVkeHUh?=
PC-14 M{C0dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{Hk[mlEPTB;MkSuOlU4OSEQvF2= NUjRWXllW0GQR1XS
Calu-6 M{fic2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXS1VlF5UUN3ME2yOU42ODdzIN88US=> NUjIb5FUW0GQR1XS
SJRH30 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzvcpRMUUN3ME2yOU43PDl4IN88US=> M3ewfXNCVkeHUh?=
ChaGo-K-1 M2L2Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTJ4LkG2Nlkh|ryP Mm[wV2FPT0WU
IA-LM M3Ht[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvjTWM2OD1{Nj6zOlQ2KM7:TR?= NE\5U5NUSU6JRWK=
GP5d M3LnZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHlcG0zUUN3ME2yOk41PDlzIN88US=> NGnnUHdUSU6JRWK=
NCI-H2291 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nFfmlEPTB;Mk[uOlU1OSEQvF2= NGnHd4RUSU6JRWK=
BALL-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mni1TWM2OD1{Nj65N|k4KM7:TR?= M3r2[nNCVkeHUh?=
HCC1954 MlezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTJ4Lkm4NFgh|ryP MkDNV2FPT0WU
NCI-H2452 M3\yZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljvTWM2OD1{Nz60NVY{KM7:TR?= NV3WOo5KW0GQR1XS
LU-99A M{LCXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LxbWlEPTB;MkeuOVU5OiEQvF2= NXvOOZoxW0GQR1XS
NTERA-S-cl-D1 NHHsR2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPWNFhPUUN3ME2yO{44Ojl7IN88US=> NEP3[|JUSU6JRWK=
PANC-10-05 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU[3SFV4UUN3ME2yO{44Pzd3IN88US=> M3;YeXNCVkeHUh?=
NCI-H2405 M1TOVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkL1TWM2OD1{Nz65N|g4KM7:TR?= M{\XcHNCVkeHUh?=
MDA-MB-415 M2DNO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknoTWM2OD1{OD60NVM4KM7:TR?= NUPCUpVYW0GQR1XS
NCI-H2342 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vlUWlEPTB;MkiuOVI5OSEQvF2= NEHCXlhUSU6JRWK=
TGBC24TKB M4\YNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LxVWlEPTB;MkiuO|EyPyEQvF2= NGXCcnZUSU6JRWK=
LU-134-A MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTJ6LkmyOlEh|ryP MmXBV2FPT0WU
SCC-4 M1;pb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3K4fGlEPTB;M{GuNFQ6PCEQvF2= M3\ue3NCVkeHUh?=
Saos-2 MoLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3faXGlEPTB;M{GuPVMxPiEQvF2= MX3TRW5ITVJ?
RERF-LC-MS MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWL4bVFQUUN3ME2zNk45OjNzIN88US=> M{[wWXNCVkeHUh?=
M14 NX\G[IVPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHETWM2OD1|Mj65O|Y1KM7:TR?= MnjuV2FPT0WU
HPAF-II MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTN|LkWwNVEh|ryP M1Ps[nNCVkeHUh?=
NCI-H1755 NYDzWZY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnZcFVKSzVyPUO0MlM{ODVizszN M2DMNHNCVkeHUh?=
D-392MG NGrN[JVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXruO|Z2UUN3ME2zOU45Pjd2IN88US=> MWnTRW5ITVJ?
A704 MnHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTN4LkC0Nlch|ryP MmjyV2FPT0WU
CP50-MEL-B NH\4WnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzNTWM2OD1|Nj6xPVEyKM7:TR?= NIf3ZW1USU6JRWK=
EW-18 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmT5TWM2OD1|Nj60OVIh|ryP M4DGR3NCVkeHUh?=
WM-115 MkjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vJOGlEPTB;M{[uPFA6QSEQvF2= MYrTRW5ITVJ?
LU-65 M{fsUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTIboxKSzVyPUO3MlE1OTdizszN M3PYR3NCVkeHUh?=
NCI-H1563 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXmNm1KSzVyPUO3MlI1QDRizszN MW\TRW5ITVJ?
DBTRG-05MG MmLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4r3N2lEPTB;M{iuNFY6OSEQvF2= NGD3bmpUSU6JRWK=
NCI-H630 NUXCRpFPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLieVRKSzVyPUO4MlQ4OTRizszN M4fUT3NCVkeHUh?=
NCI-H1155 NXmwZYJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mki5TWM2OD1|OT6yOFIh|ryP M4rZVHNCVkeHUh?=
OVACR-3 NILOSllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFT3dWFKSzVyPUO5MlkyQTVizszN MYHTRW5ITVJ?
OAW-42 NIToZY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTRyLkSyOVgh|ryP MXvTRW5ITVJ?
JVM-2 MnHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\jU5ZHUUN3ME20NU4zPDF3IN88US=> M{L4ZXNCVkeHUh?=
C3A NILPZ4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHSTWM2OD12MT6zOFQ4KM7:TR?= MWDTRW5ITVJ?
HT55 NV\0OHhRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPQ[2p[UUN3ME20Nk4zQDRzIN88US=> NF65eJJUSU6JRWK=
OVCAR-4 M3\FR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXiR|ZKSzVyPUSyMlI6PzRizszN NUnBe5hmW0GQR1XS
MEG-01 NXzqTpFXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDwenRKSzVyPUSyMlQ3OTZizszN MnnIV2FPT0WU
NCI-H82 MnzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfJTWM2OD12Mz65PFkzKM7:TR?= M{TlbXNCVkeHUh?=
JEG-3 NITJbolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlexTWM2OD12ND65OFch|ryP NUSxN|huW0GQR1XS
BPH-1 NXzLU4JWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjxTWM2OD12Nj6zPVk5KM7:TR?= MWnTRW5ITVJ?
MPP-89 M174XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHkUJBKSzVyPUS3MlI5QThizszN NGnpSHNUSU6JRWK=
ALL-PO MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnIWopYUUN3ME20O{41OTh6IN88US=> MX;TRW5ITVJ?
HT NHrZdI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGj2dJJKSzVyPUS3MlQ6OiEQvF2= NU\XdHB[W0GQR1XS
NCI-H2347 NEnscJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HGXmlEPTB;NEiuNFcyPSEQvF2= MVXTRW5ITVJ?
A2780 NWTFWYZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnH6TWM2OD12OT60NlI5KM7:TR?= MkToV2FPT0WU
KARPAS-299 NYr4WnVPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTR7LkWxNVkh|ryP MUDTRW5ITVJ?
NCI-H1651 NX7nepJyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;Xco0{UUN3ME20PU45QDJzIN88US=> M4fW[3NCVkeHUh?=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験 PD 0332991 indicates complete tumor stasis in a MDA-MB-435 xenograft at 150 mg/kg. PD 0332991 also shows broad-spectrum antitumor activity in multiple human tumor xenografts by eliminating phospho-Rb and the proliferative marker Ki-67 from tumor tissue and down-regulation of genes under the transcriptional control of E2F. [1]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

Cdk Assays:

A stock solution of PD0332991 is prepared in DMSO. CDK assays are performed in 96-well filter plates. All CDK-cyclin kinase complexes are expressed in insect cells through baculovirus infection and purified. The substrate for the assays is a fragment (amino acids 792–928) of pRb fused to GST (GST·RB-Cterm). The total volume in each well is 0.1 mL containing a final concentration of 20 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1 mM dithiothreitol, 10 mM MgCl2, 25 μM ATP (for CDK4-cyclin D1, CDK6-cyclin D2, and CDK6-cyclin D3) or 12 μM ATP (for CDK2-cyclin E, CDK2-cyclin A, and CDC2-cyclin B) containing 0.25 μCi of [γ-32P]ATP, 20 ng of enzyme, 1 μg of GST·RB-Cterm, and PD 0332991 (0.001-0.1μM). All components except the [γ-32P]ATP are added to the wells, and the plate is placed on a plate mixer for 2 min. The reaction is started by adding the [γ-32P]ATP and the plate is incubated at 25 °C for 15 min. The reaction is terminated by addition of 0.1 mL of 20% trichloroacetic acid and the plate is kept at 4  °C for at least 1 hour to allow the substrate to precipitate. The wells are then washed 5 times with 0.2 mL of 10% trichloroacetic acid and radioactive incorporation is determined with a β plate counter.
細胞試験:

[1]

+ 展開
  • 細胞株: Tumor cell lines including MDA-MB-435, ZR-75-1, T-47D, MCF-7, H1299, Colo-205, MDA-MB-468, H2009, CRRF-CEM and K562
  • 濃度: 0.01-1 μM
  • 反応時間: 24 hours
  • 実験の流れ:

    Cells are seeded at 2 × 104 per well in a 96-well plate and incubated overnight. PD 0332991 (0.01-1 μM) is added to the wells and incubated at 37 °C for another 24 hours. [14C]Thymidine (0.1 μCi) is added to each well and incorporation of the radiolabel is allowed to proceed for 72 hours. Incorporated radioactivity is determined with a β plate counter.


    (参考用のみ)
動物試験:

[1]

+ 展開
  • 動物モデル: Advanced stage human tumor xenografts including Colo-205, MDA-MB-435 breast, SF-295 glioblastoma, ZR-75-1 breast, PC-3 prostate, H125 lung, SW-620 colon, H23 lung and MDA-MB-468 breast (Rb negative) are established in severe combined immunodeficient mice.
  • 製剤: Dissolved in sodium lactate buffer (50 mM, pH 4.0)
  • 投薬量: 0-150 mg/kg
  • 投与方法: Given by gavage
    (参考用のみ)

溶解度 (25°C)

体外 Water 30 mg/mL (61.98 mM)
DMSO 3 mg/mL warmed (6.19 mM)
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
Saline
混合させたのち直ちに使用することを推奨します。
6 mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 483.99
化学式

C24H29N7O2.HCl

CAS No. 827022-32-2
保管
in solvent
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03709680 Not yet recruiting Solid Tumors|Ewing Sarcoma|Rhabdoid Tumor|Rhabdomyosarcoma|Neuroblastoma|Medulloblastoma Pfizer February 5 2019 Phase 1
NCT03609047 Not yet recruiting Breast Cancer Stage II|Breast Cancer Stage III European Organisation for Research and Treatment of Cancer - EORTC|Pfizer January 7 2019 Phase 2
NCT03691493 Not yet recruiting Anatomic Stage IV Breast Cancer AJCC v8|Estrogen Receptor Positive|HER2/Neu Negative|Metastatic Breast Carcinoma|Metastatic Malignant Neoplasm in the Bone|Progesterone Receptor Positive|Prognostic Stage IV Breast Cancer AJCC v8 Emory University|Pfizer December 1 2018 Phase 2
NCT03530696 Not yet recruiting HER2-positive Breast Cancer|Breast Cancer|Breast Cancer Stage|Recurrent Breast Cancer|Metastatic Breast Cancer|HER2 Positive Breast Carcinoma University of Arizona|Pfizer November 30 2018 Phase 2
NCT03531645 Not yet recruiting Malignant Neoplasms of Female Genital Organs M.D. Anderson Cancer Center|AstraZeneca|Pfizer November 2018 Phase 2
NCT03644186 Not yet recruiting Breast Cancer|Estrogen Receptor Positive Tumor|HER2-positive Breast Cancer International Breast Cancer Study Group|Pfizer|Hoffmann-La Roche October 2018 Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

CDKシグナル伝達経路

CDK Inhibitors with Unique Features

相関CDK製品

Tags: Palbociclib (PD-0332991) HClを買う | Palbociclib (PD-0332991) HCl ic50 | Palbociclib (PD-0332991) HCl供給者 | Palbociclib (PD-0332991) HClを購入する | Palbociclib (PD-0332991) HCl費用 | Palbociclib (PD-0332991) HCl生産者 | オーダーPalbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl化学構造 | Palbociclib (PD-0332991) HCl分子量 | Palbociclib (PD-0332991) HCl代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID